Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SSS57
- Development stage
- Unknown
- Lead developer
- 3SBio
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
SSS57 is a recombinant human activin receptor type IIB (ActRIIB)-Fc fusion protein developed by 3SBio (Shenyang Sunshine Pharmaceutical). It functions as a ligand trap for specific members of the transforming growth factor-beta (TGF-β) superfamily, such as growth differentiation factor 11 (GDF11) and activins, which are known to inhibit late-stage erythropoiesis. By binding these ligands and preventing them from signaling through endogenous receptors, SSS57 promotes the differentiation and maturation of late-stage red blood cell precursors (erythroblasts). This mechanism is intended to treat anemia in patients with myelodysplastic syndromes (MDS) and beta thalassemia. As of 2024/2025, it is undergoing Phase 1 clinical evaluation in China to assess safety, tolerability, and pharmacokinetics in healthy volunteers and postmenopausal women.
- Other names
- recombinant human activin receptor type IIB-Fc fusion protein
02
Targets
GDF11 (Growth differentiation factor 11)TRAP1 (Tumor necrosis factor receptor-associated protein 1)Activin A / Activin BGDF8 (Myostatin)
Beyond the preview
Go deeper on SSS57.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SSS57.